Cargando…

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines

Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key consider...

Descripción completa

Detalles Bibliográficos
Autores principales: Kochhar, Sonali, Excler, Jean-Louis, Kim, Denny, Robertson, James S., Fast, Patricia E., Condit, Richard C., Drew, Stephen, Wood, David, Gurwith, Marc, Klug, Bettina, Whelan, Mike, Khuri-Bulos, Najwa, Mallett Moore, Tamala, Smith, Emily R., Chen, Robert T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834840/
https://www.ncbi.nlm.nih.gov/pubmed/32747214
http://dx.doi.org/10.1016/j.vaccine.2020.07.028
Descripción
Sumario:Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed inactivated viral vaccines.